cp wire

CP Wire Articles

Pfizer Begins a Phase 1/2 Study to Evaluate RSV Vaccine

Pfizer Inc. (NYSE:PFE) announced on 5/22/18 that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common... read more

Tue, 05/22/18 - 08:30 am
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis

FibroGen, Inc. (NASDAQ:FGEN), announced on 5/21/18 that updated results from the company’s randomized, double-blind, placebo-controlled Phase 2b PRAISE study of pamrevlumab in patients with... read more

Mon, 05/21/18 - 10:44 pm
GRAIL Raises $300 Million in Series C to Pursue Early Cancer Detection Mission

GRAIL, Inc., announced on 5/21/18 that it has raised USD$300 million in an oversubscribed Series C financing. The financing is led by Ally Bridge Group, co-led by Hillhouse Capital Group and 6... read more

Mon, 05/21/18 - 10:32 pm
Microbiome Company Landscape

Virtually everyone has heard recent discussions about the microbiome and its effect on human health. It... read more
Mon, 05/21/18 - 04:47 pm
ViiV Receives EU Authorization for Juluca, the First 2-Drug, Once-Daily Pill for HIV



ViiV Healthcare, announced on 5/21/18  that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human... read more

Mon, 05/21/18 - 08:30 am

Pages